|Beigene Ltd., of Beijing||Tislelizumab||Anti-PD-1 antibody||Classical Hodgkin lymphoma||Approved by China’s NMPA for use in patients who have received at least 2 prior therapies|
|Merck & Co. Inc., of Kenilworth, N.J., and Astrazeneca plc, of Cambridge, U.K.||Lynparza (olaparib)||PARP inhibitor||Metastatic pancreatic adenocarcinoma||Approved by FDA for use as maintenance treatment in adults with deleterious or suspected deleterious germline BRCA-mutated disease that has not progressed on at least 16 weeks of first-line platinum-based chemotherapy regimen|
|Morphosys AG, of Martinsried, Germany||Tafasitamab||Anti-CD19 antibody||Relapsed or refractory diffuse large B-cell lymphoma||Submitted BLA to FDA|
|Savara Inc., of Austin, Texas||Molgradex||Inhaled formulation of recombinant human GM-CSF||Autoimmune pulmonary alveolar proteinosis||FDA granted breakthrough therapy designation|
For more information about individual companies and/or products, see Cortellis.